PharmaForceIQ's trigger-based platform doubled HCP engagement from 14% to 32% in six months.
A lacklustre launch across ophthalmology and neurology specialists suffered from delayed data and broad-reach tactics. PharmaForceIQ orchestrated journeys within 24-48 hours of lab, claims, procedure and behavioural signals, supplemented by predictive models. The page reports HCP engagement rising from 14% to 32%, new Rx share from 28% to 45% monthly and a 17% Rx lift.
PharmaForceIQ is an AI-driven HCP engagement and omnichannel orchestration company that acquired Aktana, used by pharma brands for trigger-based launch and non-personal promotion
This sits in the Scale & Govern stage of the AI use-case lifecycle: Named examples from the tools pharma teams use to monitor, govern and keep validating an AI system once it is already live in production.
Published by PharmaForceIQ on its own site — read the original case study on pharmaforceiq.com ↗
Related use cases
- 01PharmaForceIQ's AI omnichannel platform traced 97% of first-year new prescriptions to its triggers and engagements.
- 02PharmaForceIQ ran lab- and claims-triggered optichannel journeys that lifted new prescriptions 22% in 12 months.
- 03PharmaForceIQ used predictive targeting and trigger-based journeys to triple the year-one launch forecast.
- 04Day One used PharmaForceIQ optichannel marketing for a rare pediatric oncology launch with 60% of new prescribers attributed to it.
- 05PharmaForceIQ covered vacant territories with digital-only optichannel campaigns, lifting unique prescribers 41%.
- 06PharmaForceIQ used lookalike audience modelling to lift website quality visits 195% within one quarter on a small budget.